This HTML5 document contains 45 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n19http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00179906%3A_____%2F11%3A10105563%21RIV12-MZ0-00179906/
n18http://linked.opendata.cz/resource/domain/vavai/subjekt/
n14http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n16http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n4http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00179906%3A_____%2F11%3A10105563%21RIV12-MZ0-00179906
rdf:type
n14:Vysledek skos:Concept
rdfs:seeAlso
http://www.sciencedirect.com/science/article/pii/S0161642011002
dcterms:description
To confirm the safety and compare the efficacy of intravitreal pegaptanib sodium 0,3mg versus sham injection in subject with diabetic macular edema (DME). 36,8% subjects from the pegaptanib group versus 19,7% subjects from the sham group experienced a VA improvement of 10 letters at week 54. At week 102, pegaptanib treated subjects gained, on average, 6,1 letters versus 1,3 letters for sham (P0,01). These findings indicate that intravitreal pegaptanib is effective in the traetment of DME and has positive safety profile. To confirm the safety and compare the efficacy of intravitreal pegaptanib sodium 0,3mg versus sham injection in subject with diabetic macular edema (DME). 36,8% subjects from the pegaptanib group versus 19,7% subjects from the sham group experienced a VA improvement of 10 letters at week 54. At week 102, pegaptanib treated subjects gained, on average, 6,1 letters versus 1,3 letters for sham (P0,01). These findings indicate that intravitreal pegaptanib is effective in the traetment of DME and has positive safety profile.
dcterms:title
A Phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema A Phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema
skos:prefLabel
A Phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema A Phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema
skos:notation
RIV/00179906:_____/11:10105563!RIV12-MZ0-00179906
n14:predkladatel
n18:ico%3A00179906
n3:aktivita
n11:I n11:N
n3:aktivity
I, N
n3:cisloPeriodika
6
n3:dodaniDat
n4:2012
n3:domaciTvurceVysledku
n10:2737000
n3:druhVysledku
n13:J
n3:duvernostUdaju
n17:S
n3:entitaPredkladatele
n19:predkladatel
n3:idSjednocenehoVysledku
184053
n3:idVysledku
RIV/00179906:_____/11:10105563
n3:jazykVysledku
n8:eng
n3:klicovaSlova
diabetic macular edema; pegaptanib sodium
n3:klicoveSlovo
n9:pegaptanib%20sodium n9:diabetic%20macular%20edema
n3:kodStatuVydavatele
NL - Nizozemsko
n3:kontrolniKodProRIV
[F6EABF2F6247]
n3:nazevZdroje
Ophthalmology
n3:obor
n7:FF
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
145
n3:rokUplatneniVysledku
n4:2011
n3:svazekPeriodika
118
n3:tvurceVysledku
Dombi, T. Sultan, M. B. Dusová, Jaroslava Macugen 1013, Study Group Ice, K. S. Loftus, J. Zhou, D.
n3:wos
000291152700016
s:issn
0161-6420
s:numberOfPages
12
n16:doi
10.1016/j.ophtha.2011.02.045